Abstract
Aims
To investigate the effect of intravitreal dexamethasone implant (IVD) on central foveal thickness (CFT), choroidal thickness (CT) and its correlation with visual acuity in eyes with refractory diabetic macular oedema (DMO).
Methods
This was a retrospective interventional case-series. Thirty-five eyes of 35 patients were treated with a single injection of IVD because of refractory DMO with CFT over 300 μm, and persistent intraretinal and subretinal fluid despite of multiple intravitreal bevacizumab injections. Patients were followed-up for 6 months for the evaluation of CFT and subfoveal CT by spectral-domain optical coherence tomography.
Results
All eyes (mean age: 59.4±12.35 years; 18 males, 17 females) had been previously treated with multiple bevacizumab injections and showed persistent DMO (mean number of injections 4.08±2.98) The preoperative logMAR BCVA was 0.49±0.24, which gradually improved to 0.46±0.32 at 6 months (P=0.652) and 26% gained two or more lines of Snellen visual acuity. At baseline, the mean CFT was 526.29±123.48 μm, which significantly improved to 316.15±100.09 μm at 3 months (P<0.001). However, CFT deteriorated to 457.07±136.53 μm at 6 months (P=0.051). Similarly, the mean preoperative subfoveal CT was 288.91±36.47 μm and it decreased to 266.85±30.93 μm at 3 months (P<0.01), but increased to 278.63±32.55 μm at 6 months (P=0.137). The reduction of CFT from baseline showed significant correlation with that of subfoveal CT at 3 months (P=0.041) and at 6 months (P=0.008).
Conclusions
In DMO refractory to multiple bevacizumab injections, IVD significantly reduced CFT and subfoveal CT, with BCVA improvement in one-fourth of the patients. The reduction of CFT showed significant correlation with reduction of subfoveal CT.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Antonetti DA, Klein R, Gardner TW . Diabetic retinopathy. N Engl J Med 2012; 366 (13): 1227–1239.
Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118 (4): 445–450.
Arimura N, Otsuka H, Yamakiri K, Sonoda Y, Nakao S, Noda Y et al. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy. Ophthalmology 2009; 116 (5): 921–926.
Funatsu H, Noma H, Mimura T, Eguchi S . Vitreous inflammatory factors and macular oedema. Br J Ophthalmol 2012; 96 (2): 302–304.
Funatsu H, Noma H, Mimura T, Eguchi S, Hori S . Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 2009; 116 (1): 73–79.
Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013; 120 (10): 2013–2022.
Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014; 121 (10): 1904–1914.
Gillies MC, Lim LL, Campain A, Quin GJ, Salem W, Li J et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology 2014; 121 (12): 2473–2481.
Lazic R, Lukic M, Boras I, Draca N, Vlasic M, Gabric N et al. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant. Retina 2014; 34 (4): 719–724.
Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010; 128 (3): 289–296.
Pacella E, Vestri AR, Muscella R, Carbotti MR, Castellucci M, Coi L et al. Preliminary results of an intravitreal dexamethasone implant (Ozurdex(R)) in patients with persistent diabetic macular edema. Clin Ophthalmol 2013; 7: 1423–1428.
Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh H, Li XY et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011; 31 (5): 915–923.
Jonas JB, Forster TM, Steinmetz P, Schlichtenbrede FC, Harder BC . Choroidal thickness in age-related macular degeneration. Retina 2014; 34 (6): 1149–1155.
Kim JT, Lee DH, Joe SG, Kim JG, Yoon YH . Changes in choroidal thickness in relation to the severity of retinopathy and macular edema in type 2 diabetic patients. Invest Ophthalmol Vis Sci 2013; 54 (5): 3378–3384.
Kim M, Kim H, Kwon HJ, Kim SS, Koh HJ, Lee SC . Choroidal thickness in Behcet's uveitis: an enhanced depth imaging-optical coherence tomography and its association with angiographic changes. Invest Ophthalmol Vis Sci 2013; 54 (9): 6033–6039.
Sonoda S, Sakamoto T, Yamashita T, Otsuka H, Shirasawa M, Kakiuchi N et al. Effect of intravitreal triamcinolone acetonide or bevacizumab on choroidal thickness in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci 2014; 55 (6): 3979–3985.
Cao J, McLeod S, Merges CA, Lutty GA . Choriocapillaris degeneration and related pathologic changes in human diabetic eyes. Arch Ophthalmol 1998; 116 (5): 589–597.
Freyler H, Prskavec F, Stelzer N . Diabetic choroidopathy—a retrospective fluorescein angiography study. Preliminary report. Klin Monbl Augenheilkd 1986; 189 (2): 144–147.
Hua R, Liu L, Wang X, Chen L . Imaging evidence of diabetic choroidopathy in vivo: angiographic pathoanatomy and choroidal-enhanced depth imaging. PLoS One 2013; 8 (12): e83494.
Regatieri CV, Branchini L, Carmody J, Fujimoto JG, Duker JS . Choroidal thickness in patients with diabetic retinopathy analyzed by spectral-domain optical coherence tomography. Retina 2012; 32 (3): 563–568.
Unsal E, Eltutar K, Zirtiloglu S, Dincer N, Ozdogan Erkul S, Gungel H . Choroidal thickness in patients with diabetic retinopathy. Clin Ophthalmol 2014; 8: 637–642.
Gerendas BS, Waldstein SM, Simader C, Deak G, Hajnajeeb B, Zhang L et al. Three-dimensional automated choroidal volume assessment on standard spectral-domain optical coherence tomography and correlation with the level of diabetic macular edema. Am J Ophthalmol 2014; 158 (5): 1039–1048.
Yiu G, Manjunath V, Chiu SJ, Farsiu S, Mahmoud TH . Effect of anti-vascular endothelial growth factor therapy on choroidal thickness in diabetic macular edema. Am J Ophthalmol 2014; 158 (4): 745–751 e742.
McLeod DS, Lefer DJ, Merges C, Lutty GA . Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. Am J Pathol 1995; 147 (3): 642–653.
Hidayat AA, Fine BS . Diabetic choroidopathy. Light and electron microscopic observations of seven cases. Ophthalmology 1985; 92 (4): 512–522.
Fryczkowski AW, Sato SE, Hodes BL . Changes in the diabetic choroidal vasculature: scanning electron microscopy findings. Ann Ophthalmol 1988; 20 (8): 299–305.
Wang K, Wang Y, Gao L, Li X, Li M, Guo J . Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull 2008; 31 (8): 1541–1546.
Tamura H, Miyamoto K, Kiryu J, Miyahara S, Katsuta H, Hirose F et al. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 2005; 46 (4): 1440–1444.
Antonetti DA, Wolpert EB, DeMaio L, Harhaj NS, Scaduto RC Jr . Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J Neurochem 2002; 80 (4): 667–677.
Liu Y, Mladinov D, Pietrusz JL, Usa K, Liang M . Glucocorticoid response elements and 11 beta-hydroxysteroid dehydrogenases in the regulation of endothelial nitric oxide synthase expression. Cardiovasc Res 2009; 81 (1): 140–147.
Yamamoto Y, Gaynor RB . Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001; 107 (2): 135–142.
Kim M, Kim SS, Kwon HJ, Koh HJ, Lee SC . Association between choroidal thickness and ocular perfusion pressure in young, healthy subjects: enhanced depth imaging optical coherence tomography study. Invest Ophthalmol Vis Sci 2012; 53 (12): 7710–7717.
Dong N, Xu B, Wang B, Chu L . Study of 27 aqueous humor cytokines in patients with type 2 diabetes with or without retinopathy. Mol Vis 2013; 19: 1734–1746.
Yoshimura T, Sonoda KH, Sugahara M, Mochizuki Y, Enaida H, Oshima Y et al. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One 2009; 4 (12): e8158.
Funatsu H, Yamashita H, Noma H, Mimura T, Nakamura S, Sakata K et al. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol 2005; 243 (1): 3–8.
Oh IK, Kim SW, Oh J, Lee TS, Huh K . Inflammatory and angiogenic factors in the aqueous humor and the relationship to diabetic retinopathy. Curr Eye Res 2010; 35 (12): 1116–1127.
Sonoda S, Sakamoto T, Yamashita T, Shirasawa M, Otsuka H, Sonoda Y . Retinal morphologic changes and concentrations of cytokines in eyes with diabetic macular edema. Retina 2014; 34 (4): 741–748.
Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109 (5): 920–927.
Moshfeghi DM, Kaiser PK, Scott IU, Sears JE, Benz M, Sinesterra JP et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003; 136 (5): 791–796.
Jaissle GB, Szurman P, Bartz-Schmidt KU . Ocular side effects and complications of intravitreal triamcinolone acetonide injection. Ophthalmologe 2004; 101 (2): 121–128.
Acknowledgements
This study was supported by a Faculty Research Grant of Yonsei University College of Medicine for 2012 (3-2012-0137).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Kim, M., Cho, Y., Lee, C. et al. Effect of intravitreal dexamethasone implant on retinal and choroidal thickness in refractory diabetic macular oedema after multiple anti-VEGF injections. Eye 30, 718–725 (2016). https://doi.org/10.1038/eye.2016.23
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2016.23
This article is cited by
-
Prognostic value of choroidal vascular index in determining response to intravitreal dexamethasone implant treatment used in refractory diabetic macular edema
Lasers in Medical Science (2023)
-
Dexamethasone suppresses the proliferation and migration of VSMCs by FAK in high glucose conditions
BMC Pharmacology and Toxicology (2022)
-
Efficacy and safety of single-dose dexamethasone implantation for patients with persistent diabetic macular edema: a systematic review and meta-analysis
Graefe's Archive for Clinical and Experimental Ophthalmology (2022)
-
Intravitreal dexamethasone implant Ozurdex® in naïve and refractory patients with different subtypes of diabetic macular edema
BMC Ophthalmology (2019)
